HK StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Aesthetic Medicine

1,118.805

+65.9416.26%

Number of Gainers:8

Number of Losers:2

Number of Flat:3

PE:- -

High:1,124.029

Open:1,052.617

Low:1,042.088

Close:1,052.864

Volume:106.54M

Turnover:1.30B

Market Cap:185.02B

Float Cap:138.67B

Loading ...

Angelalign Technology (SEHK:6699) Valuation Check As 2025 Profit Guidance Signals Stronger Earnings Outlook

Simply Wall St.

CMS Reports 2025 Financial Results: Profit Attributable to Owners Declines 8.08% to Approximately 1.489 Billion Yuan

China Medical System FY2025 profit fell 10.5% to RMB1.44 billion as turnover rose 9.9% to RMB8.21 billion

China Medical System Holdings - Profit for Year RMB1,443.3 Mln

THOMSON REUTERS

China Medical System Holdings - Proposed Final Dividend of RMB0.1366 per Share

THOMSON REUTERS

FOSUN PHARMA's HLX07 Combined with Serplulimab Injection and Chemotherapy Cleared for Clinical Trial in Advanced Squamous Non-Small Cell Lung Cancer

HAOHAI BIOTEC (06826) Obtains Medical Device Registration Certificate for Ophthalmic Cross-linked Sodium Hyaluronate Gel

Modern Dental Issues Profit Alert, Anticipates 2025 Net Profit Between HK$590 Million and HK$610 Million

Modern Dental - FY2025 Revenue Expected at HK$3,675 Mln-HK$3,775 Mln

THOMSON REUTERS

Modern Dental Group - Expected Result Due to Organic Growth, Others in FY

THOMSON REUTERS

Modern Dental Group forecasts FY2025 net profit of HKD 590-610 million up 45-49.9%

Modern Dental Group sets board meeting to approve annual results and consider dividend

Fosun Pharmaceutical Gets Chinese Regulator's Nod for Clinical Trials of Blood Cancer Drug

MT Newswires Live

Assessing China Medical System (SEHK:867) Valuation After A Recent Share Price Pullback

Simply Wall St.

China-Myanmar Border Crossing at Ruili Port Surpasses One Million Travelers This Year

China Medical System Holdings - Nmpa Approves Desidustat Tablets for Renal Anaemia in China

THOMSON REUTERS

China Medical System Gets China Nod to Market Renal Anaemia Drug

BRIEF-Lai Fung Expects Half-Year Loss To Increase By No Less Than 100%

CMS Gains Chinese Approval for New Anemia Drug Desidustat

China Medical System Holdings - New Drug for Renal Anaemia Desidustat Tablets Approved for Marketing by China Nmpa

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/BK1593/news?page=4"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK1593","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1593\",,,,,undefined,":{"symbol":"BK1593","market":"HK","secType":"PLATE","nameCN":"Aesthetic Medicine","latestPrice":1118.805,"timestamp":1774598898612,"preClose":1052.8644,"halted":0,"volume":106539081,"delay":0,"changeRate":0.06263,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Market Closed","change":65.940674,"latestTime":"03-27 16:00:00","open":1052.6166,"high":1124.0287,"low":1042.0875,"amount":1296768934,"amplitude":0.077827,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1774834200000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1774575000000,1774584000000],[1774587600000,1774598400000]],"pbRate":1.601651,"peRate":24.28463,"turnoverRate":0.005253,"increases":8,"decrements":2,"flats":3,"marketCap":185021694928,"floatMarketCap":138668828432},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1593\",,,,,undefined,":{"symbol":"BK1593","high":1124.0287,"amplitude":0.077827,"preClose":1052.8644,"low":1042.0875,"pbRate":"1.601651","latestPrice":1118.805,"volume":106539081,"delay":0,"open":1052.6166,"prevYearClose":1094.978,"prevWeekClose":1084.158,"prevMonthClose":1133.252,"prevQuarterClose":1094.978,"fiveDayClose":1084.158,"twentyDayClose":1133.252,"sixtyDayClose":1116.869,"secType":"PLATE","market":"HK","turnoverRate":0.005253,"peRate":24.28463,"marketCap":185021694928,"floatMarketCap":138668828432,"timestamp":1774598898612,"nameCN":"Aesthetic Medicine"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1593\",,,,undefined,":{"bkCode":"BK1593","up":8,"down":2,"flat":3},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1593\",pageSize:20,pageCount:4,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2620393496","title":"Angelalign Technology (SEHK:6699) Valuation Check As 2025 Profit Guidance Signals Stronger Earnings Outlook","url":"https://stock-news.laohu8.com/highlight/detail?id=2620393496","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620393496?lang=en_us&edition=fundamental","pubTime":"2026-03-17 02:20","pubTimestamp":1773685252,"startTime":"0","endTime":"0","summary":"Angelalign Technology (SEHK:6699) has issued fresh 2025 earnings guidance, projecting net profit of about US$24 million to US$30 million, compared with roughly US$10 million in 2024, highlighting stronger clear aligner demand and cost timing effects.\nSee our latest analysis for Angelalign Technology.\nAngelalign Technology's shares have rallied in recent months, with a 90 day share price return of 17.51% and year to date share price return of 16.26%. However, the 3 year total shareholder...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6021000-choice1-main-header/1585186659638","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6021000-choice1-main-header/1585186659638"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/healthcare/hkg-6699/angelalign-technology-shares/news/angelalign-technology-sehk6699-valuation-check-as-2025-profi","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/healthcare/hkg-6699/angelalign-technology-shares/news/angelalign-technology-sehk6699-valuation-check-as-2025-profi","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK1100","06699","BK1587","BK1583","BK1593","DCF"],"gpt_icon":0},{"id":"1187030708","title":"CMS Reports 2025 Financial Results: Profit Attributable to Owners Declines 8.08% to Approximately 1.489 Billion Yuan","url":"https://stock-news.laohu8.com/highlight/detail?id=1187030708","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1187030708?lang=en_us&edition=fundamental","pubTime":"2026-03-16 22:56","pubTimestamp":1773672998,"startTime":"0","endTime":"0","summary":"CMS announced its 2025 financial performance, with revenue increasing by 9.95% year-over-year to 8.212 billion yuan. Profit attributable to owners was approximately 1.489 billion yuan, a decrease of...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2488822045.USD","IE00BYV24P56.USD","BK1593","SG9999004220.SGD","IE00BMCWC346.EUR","BK1191","00867","IE00BVYPNP33.GBP","SG9999015952.SGD","IE00BVYPNQ40.USD","SG9999015945.SGD","SG9999015978.USD","SG9999015986.USD","IE00BGHQDM52.EUR"],"gpt_icon":0},{"id":"2619546435","title":"China Medical System FY2025 profit fell 10.5% to RMB1.44 billion as turnover rose 9.9% to RMB8.21 billion","url":"https://stock-news.laohu8.com/highlight/detail?id=2619546435","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619546435?lang=en_us&edition=fundamental","pubTime":"2026-03-16 22:44","pubTimestamp":1773672290,"startTime":"0","endTime":"0","summary":"China Medical System published an annual results announcement reporting FY2025 turnover up 9.9% to RMB8.21 billion. FY2025 gross profit rose 8.3% to RMB5.87 billion, while profit for the year fell 10.5% to RMB1.44 billion. Basic earnings per share declined 7.8% to RMB0.6154, and bank balances and cash were RMB2.7 billion at Dec. 31, 2025. The company proposed a FY2025 final dividend of RMB0.1366 per share, bringing the FY2025 total dividend up 9% to RMB0.2921 per share. Management said FY2025 profit was affected by non-recurring and non-operational items, including a one-off RMB278.8 million payment related to repayment of a local income tax concession for 2022-2024 and a late payment surcharge.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal a","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260316:nNDLbF9BGz:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00867","IE00BVYPNP33.GBP","IE00BYV24P56.USD","SG9999015952.SGD","IE00BMCWC346.EUR","IE00BVYPNQ40.USD","BK1191","SG9999015986.USD","SG9999015978.USD","SG9999015945.SGD","BK1593","IE00BGHQDM52.EUR","SG9999004220.SGD","LU2488822045.USD"],"gpt_icon":0},{"id":"2619046433","title":"China Medical System Holdings -  Profit for Year RMB1,443.3 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2619046433","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619046433?lang=en_us&edition=fundamental","pubTime":"2026-03-16 22:44","pubTimestamp":1773672263,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260316:nFWN4040GI:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SG9999004220.SGD","00867","IE00BVYPNP33.GBP","SG9999015978.USD","IE00BGHQDM52.EUR","IE00BVYPNQ40.USD","IE00BYV24P56.USD","SG9999015952.SGD","SG9999015945.SGD","BK1191","SG9999015986.USD","LU2488822045.USD","BK1593","IE00BMCWC346.EUR"],"gpt_icon":0},{"id":"2619464331","title":"China Medical System Holdings - Proposed Final Dividend of RMB0.1366 per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2619464331","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619464331?lang=en_us&edition=fundamental","pubTime":"2026-03-16 22:44","pubTimestamp":1773672255,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260316:nFWN4040IF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["00867","SG9999015952.SGD","SG9999015945.SGD","BK1191","SG9999015978.USD","IE00BVYPNP33.GBP","BK1593","SG9999004220.SGD","IE00BVYPNQ40.USD","LU2488822045.USD","IE00BMCWC346.EUR","SG9999015986.USD","IE00BGHQDM52.EUR","IE00BYV24P56.USD"],"gpt_icon":0},{"id":"1188326337","title":"FOSUN PHARMA's HLX07 Combined with Serplulimab Injection and Chemotherapy Cleared for Clinical Trial in Advanced Squamous Non-Small Cell Lung Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=1188326337","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1188326337?lang=en_us&edition=fundamental","pubTime":"2026-03-16 18:50","pubTimestamp":1773658232,"startTime":"0","endTime":"0","summary":"FOSUN PHARMA (600196.SH) announced that its subsidiary, Shanghai Henlius Biotech, Inc., and its controlled subsidiaries recently received approval from the National Medical Products Administration to...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0188","BK0239","BK0012","600196","BK0175","BK0196","02196","BK0060","BK0183","BK0028","BK0096","BK1191","BK1515","BK1593","BK0187"],"gpt_icon":0},{"id":"1109606667","title":"HAOHAI BIOTEC (06826) Obtains Medical Device Registration Certificate for Ophthalmic Cross-linked Sodium Hyaluronate Gel","url":"https://stock-news.laohu8.com/highlight/detail?id=1109606667","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1109606667?lang=en_us&edition=fundamental","pubTime":"2026-03-16 18:40","pubTimestamp":1773657624,"startTime":"0","endTime":"0","summary":"HAOHAI BIOTEC (06826) has announced that its wholly-owned subsidiary, Shanghai Qisheng Biological Preparations Co., Ltd., recently received a Medical Device Registration Certificate from the National Medical Products Administration for its ophthalmic cross-linked sodium hyaluronate gel product.","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09996","BK1100","BK1222","BK1574","159883","BK1161","BK1593","BK1583","06826","09997"],"gpt_icon":0},{"id":"1175776314","title":"Modern Dental Issues Profit Alert, Anticipates 2025 Net Profit Between HK$590 Million and HK$610 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=1175776314","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1175776314?lang=en_us&edition=fundamental","pubTime":"2026-03-16 18:40","pubTimestamp":1773657623,"startTime":"0","endTime":"0","summary":"Modern Dental (03600) has announced that the Group expects: (i) revenue for the fiscal year ending December 31, 2025 (2025 fiscal year) to be between HK$3.675 billion and HK$3.775 billion,...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1100","BK1583","03600","BK1593"],"gpt_icon":0},{"id":"2619745489","title":"Modern Dental - FY2025 Revenue Expected at HK$3,675 Mln-HK$3,775 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2619745489","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619745489?lang=en_us&edition=fundamental","pubTime":"2026-03-16 18:32","pubTimestamp":1773657149,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260316:nFWN40406I:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["03600","BK1583","BK1100","BK1593"],"gpt_icon":0},{"id":"2619454899","title":"Modern Dental Group - Expected Result Due to Organic Growth, Others in FY","url":"https://stock-news.laohu8.com/highlight/detail?id=2619454899","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619454899?lang=en_us&edition=fundamental","pubTime":"2026-03-16 18:32","pubTimestamp":1773657149,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260316:nFWN40406I:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1593","03600","BK1583","BK1100"],"gpt_icon":0},{"id":"2619454845","title":"Modern Dental Group forecasts FY2025 net profit of HKD 590-610 million up 45-49.9%","url":"https://stock-news.laohu8.com/highlight/detail?id=2619454845","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619454845?lang=en_us&edition=fundamental","pubTime":"2026-03-16 18:32","pubTimestamp":1773657133,"startTime":"0","endTime":"0","summary":"Modern Dental expects FY 2025 revenue of HKD 3.68-3.78 billion, up 9.2%-12.2% from HKD 3.36 billion in FY 2024. It forecasts FY 2025 EBITDA of HKD 0.92-0.95 billion, up 29.8%-34% from HKD 0.71 billion. Net profit is expected at HKD 0.59-0.61 billion, up 45%-49.9% from HKD 0.41 billion. The company attributed the revenue increase to organic growth in Europe and Australia and the January 2025 acquisition of Hexa Ceram. It cited higher digital-solution case mix, favorable FX moves including a stronger euro, and contributions from Hexa Ceram and Digital Sleep Design as drivers of EBITDA and profit growth.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Modern Dental Group Ltd. published the original content used to generate this news brief ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260316:nNDL2pqGJd:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03600","BK1583","BK1100","BK1593"],"gpt_icon":0},{"id":"2619453151","title":"Modern Dental Group sets board meeting to approve annual results and consider dividend","url":"https://stock-news.laohu8.com/highlight/detail?id=2619453151","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619453151?lang=en_us&edition=fundamental","pubTime":"2026-03-16 16:39","pubTimestamp":1773650386,"startTime":"0","endTime":"0","summary":"Modern Dental Group said its board will meet on 26 March 2026 to consider and approve the group’s final results for the year ended 31 December 2025. The board will also consider a dividend at the meeting.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Modern Dental Group Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on March 16, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260316:nNDL2PDT2F:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03600","BK1583","BK1100","BK1593"],"gpt_icon":0},{"id":"2619453250","title":"Fosun Pharmaceutical Gets Chinese Regulator's Nod for Clinical Trials of Blood Cancer Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2619453250","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619453250?lang=en_us&edition=fundamental","pubTime":"2026-03-16 16:39","pubTimestamp":1773650355,"startTime":"0","endTime":"0","summary":"China's drug regulator approved Shanghai Fosun Pharmaceutical's (SHA:600196, HKG:2196) clinical trials for its FXS0683 tablets, according to a Saturday filing with the Shanghai bourse.The drug is indicated for blood cancers, helps prevent tumor growth, the filing said.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0175","BK0028","BK0183","600196","BK1515","BK0188","BK0239","BK0012","BK0096","BK1593","BK1191","BK0196","BK0060","BK0187","02196"],"gpt_icon":0},{"id":"2619483124","title":"Assessing China Medical System (SEHK:867) Valuation After A Recent Share Price Pullback","url":"https://stock-news.laohu8.com/highlight/detail?id=2619483124","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619483124?lang=en_us&edition=fundamental","pubTime":"2026-03-14 22:25","pubTimestamp":1773498313,"startTime":"0","endTime":"0","summary":"Recent share performance and business snapshot\nChina Medical System Holdings (SEHK:867) has drawn investor attention after a recent share price pullback, with the stock posting a 4.1% decline over the past day and a 16.3% decline over the past month.\nOver the past 3 months, the stock has recorded a 6.3% decline, while the 1 year total return stands at 55.1%. In the longer term, the 3 year total return is 13.4% and the 5 year total return reflects a 12.3% decline.\nThe company reports annual...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-867/china-medical-system-holdings-shares/news/assessing-china-medical-system-sehk867-valuation-after-a-rec","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-867/china-medical-system-holdings-shares/news/assessing-china-medical-system-sehk867-valuation-after-a-rec","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU2488822045.USD","DCF","SG9999015945.SGD","IE00BGHQDM52.EUR","IE00BVYPNP33.GBP","SG9999015986.USD","SG9999015978.USD","IE00BVYPNQ40.USD","IE00BYV24P56.USD","BK1191","IE00BMCWC346.EUR","00867","SG9999015952.SGD","BK1593","SG9999004220.SGD"],"gpt_icon":0},{"id":"1107206881","title":"China-Myanmar Border Crossing at Ruili Port Surpasses One Million Travelers This Year","url":"https://stock-news.laohu8.com/highlight/detail?id=1107206881","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1107206881?lang=en_us&edition=fundamental","pubTime":"2026-03-14 15:00","pubTimestamp":1773471642,"startTime":"0","endTime":"0","summary":"As of March 13 at 3:00 PM, the number of travelers passing through the Ruili Port on the China-Myanmar border has exceeded one million since the beginning of the year, marking an 8.7% increase...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1209","BK1593","02135"],"gpt_icon":0},{"id":"2619118902","title":"China Medical System Holdings - Nmpa Approves Desidustat Tablets for Renal Anaemia in China","url":"https://stock-news.laohu8.com/highlight/detail?id=2619118902","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619118902?lang=en_us&edition=fundamental","pubTime":"2026-03-13 21:54","pubTimestamp":1773410083,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260313:nFWN4010L0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1593","BK1191","00867","IE00BVYPNQ40.USD","SG9999015952.SGD","SG9999015986.USD","SG9999015978.USD","SG9999004220.SGD","SG9999015945.SGD","IE00BVYPNP33.GBP","IE00BYV24P56.USD","IE00BGHQDM52.EUR","IE00BMCWC346.EUR","LU2488822045.USD"],"gpt_icon":0},{"id":"2619192249","title":"China Medical System Gets China Nod to Market Renal Anaemia Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2619192249","media":"MT Newswires","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619192249?lang=en_us&edition=fundamental","pubTime":"2026-03-13 20:35","pubTimestamp":1773405323,"startTime":"0","endTime":"0","summary":"China Medical System (HKG:0867, SGX:8A8) obtained marketing approval for renal anaemia drug Desidustat Tablets from China's National Medical Products Administration,The product is used for treating anaemia in non-dialysis adult patients with chronic kidney disease.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1593","BK1191","LU2488822045.USD","IE00BMCWC346.EUR","IE00BGHQDM52.EUR","IE00BVYPNQ40.USD","SG9999015945.SGD","SG9999015952.SGD","00867","IE00BYV24P56.USD","SG9999004220.SGD","SG9999015986.USD","SG9999015978.USD","8A8.SI","BK6079","IE00BVYPNP33.GBP"],"gpt_icon":0},{"id":"2619962491","title":"BRIEF-Lai Fung Expects Half-Year Loss To Increase By No Less Than 100%","url":"https://stock-news.laohu8.com/highlight/detail?id=2619962491","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619962491?lang=en_us&edition=fundamental","pubTime":"2026-03-13 18:55","pubTimestamp":1773399345,"startTime":"0","endTime":"0","summary":"BRIEF-Lai Fung Expects Half-Year Loss To Increase By No Less Than 100%March 13  - Lai Fung Holdings Ltd 1125.HK:EXPECTS HY LOSS TO INCREASE BY NO LESS THAN 100%EXPECTED RESULT DUE TO SALE OF ACCOMMODATION TOWER IN HY, OTHERSFurther company coverage: 1125.HK ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260313:nFWN4001XF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1593","BK1240","01125"],"gpt_icon":0},{"id":"1143602131","title":"CMS Gains Chinese Approval for New Anemia Drug Desidustat","url":"https://stock-news.laohu8.com/highlight/detail?id=1143602131","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1143602131?lang=en_us&edition=fundamental","pubTime":"2026-03-13 18:49","pubTimestamp":1773398986,"startTime":"0","endTime":"0","summary":"CMS (00867) announced that the marketing authorization application for its new renal anemia drug, Desidustat Tablets, was approved by China's National Medical Products Administration (NMPA) on March...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999004220.SGD","00867","IE00BVYPNP33.GBP","SG9999015978.USD","IE00BGHQDM52.EUR","IE00BVYPNQ40.USD","IE00BYV24P56.USD","SG9999015952.SGD","SG9999015945.SGD","BK1191","SG9999015986.USD","LU2488822045.USD","BK1593","IE00BMCWC346.EUR"],"gpt_icon":0},{"id":"2619919663","title":"China Medical System Holdings -  New Drug for Renal Anaemia Desidustat Tablets Approved for Marketing by China Nmpa","url":"https://stock-news.laohu8.com/highlight/detail?id=2619919663","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619919663?lang=en_us&edition=fundamental","pubTime":"2026-03-13 18:44","pubTimestamp":1773398652,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260313:nFWN40104G:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IE00BMCWC346.EUR","SG9999015978.USD","IE00BYV24P56.USD","IE00BGHQDM52.EUR","BK1191","BK1593","IE00BVYPNP33.GBP","IE00BVYPNQ40.USD","SG9999015945.SGD","SG9999004220.SGD","SG9999015986.USD","LU2488822045.USD","00867","SG9999015952.SGD"],"gpt_icon":0}],"pageSize":20,"totalPage":5,"pageCount":4,"totalSize":87,"code":"91000000","status":"200"}]}}